The molecular mechanisms of hypertriglyceridemia (HTG), a common lipid metabolic disorder in humans, often of genetic origin, are not well understood. In studying the effect of apolipoprotein (apo) E on the metabolism of triglyceride-rich lipoproteins, we found that expressing high plasma levels of human apoE3 in transgenic mice lacking endogenous mouse apoE caused HTG. These transgenic animals had 3-fold higher plasma triglyceride levels, higher very low density lipoproteins (VLDL), and lower high density lipoproteins than did nontransgenics. Removing one or both low density lipoprotein receptor alleles in the apoE3-overexpressing mice caused severe HTG (8 -11-fold over nontransgenics) and increased VLDL and decreased low and high density lipoproteins, and apoE3-enriched VLDL were markedly depleted in apoC-II. At least two mechanisms could explain HTG associated with apoE3 overexpression: stimulated VLDL triglyceride production and impaired VLDL lipolysis. The apoE3 mice with HTG had a 50% increase in hepatic VLDL triglyceride production. Furthermore, overexpression of apoE (E2, E3, or E4) in cultured hepatocytes (McA-RH7777 cells) correlated positively with secretion of VLDL into the medium. However, apoE3 overexpressionassociated HTG was only partially explained by VLDL overproduction, as lipoprotein lipase-mediated VLDL lipolysis was also decreased 20 -86% depending on apoE3 levels, most likely by displacing or masking apoC-II on the particles. In human subjects, HTG correlated positively with increased VLDL triglyceride and plasma and VLDL apoE levels. However, plasma and VLDL apoE correlated negatively with VLDL apoC-II levels and lipoprotein lipase-mediated VLDL lipolysis. Thus, optimal expression of apoE is crucial for normal metabolism of triglyceriderich lipoproteins, and overexpression and/or accumulation of apoE may contribute to HTG by stimulating VLDL triglyceride production and by impairing VLDL lipolysis. The apoE3-overexpressing mice will be useful for studying the pathophysiology of this disorder.
1 a common inherited disorder of lipid metabolism in humans, is characterized by a proatherogenic lipoprotein profile, including increased plasma triglycerides and very low density lipoproteins (VLDL), and often decreased high density lipoproteins (HDL) (1) (2) (3) . Whereas its frequency in the general population is ϳ1% (1), HTG occurs in ϳ5% of patients surviving a myocardial infarction (4, 5) , indicating an increased risk for atherosclerosis (6) . Investigations of the pathogenesis of HTG have suggested both increased VLDL triglyceride production (2, 7) and reduced VLDL catabolism (7, 8) ; however, the molecular mechanism of HTG remains unknown.
In humans and rodents, plasma triglycerides are transported mostly by intestine-derived chylomicrons and liver-derived VLDL. One of the major protein constituents of these triglyceride-rich lipoproteins (9) , apolipoprotein (apo) E, serves as a high affinity ligand for several hepatic lipoprotein receptors, including the low density lipoprotein (LDL) receptor and the LDL receptor-related protein, and for cell-surface heparan sulfate proteoglycans (10 -12) . By interacting with these receptors or with heparan sulfate proteoglycans, apoE mediates the clearance of triglyceride-rich lipoproteins and their remnants from the circulation (10, 12) . Thus, structural mutations of apoE cause significant alterations in triglyceride-rich lipoprotein metabolism, such as type III hyperlipoproteinemia, which is characterized by both hypercholesterolemia and HTG (10) .
Recently, clinical studies have shown that plasma levels of apoE are also important determinants of the metabolism of triglyceride-rich lipoproteins (13) . In fact, 20 -40% of the variability of triglyceride levels in humans can be explained by plasma apoE concentrations (13) , which are independent of apoE polymorphism (14) . In the present study, we investigated the effect of apoE3 expression levels on plasma triglyceriderich lipoprotein metabolism in both transgenic mice and humans. Our data indicate that overexpression and accumulation of apoE may contribute to HTG by stimulating hepatic VLDL triglyceride production and by impairing VLDL lipolysis.
EXPERIMENTAL PROCEDURES
Materials-A Superose 6 column purchased from Amersham Pharmacia Biotech was used on a Pharmacia fast protein liquid chromatography system. Cholesterol and triglyceride standards were from Abbott (North Chicago, IL) and Boehringer Mannheim (Mannheim, Germany), respectively. The automated system for lipid analysis (Kinetic Microplate Reader) was from Molecular Devices (Menlo Park, CA). Triton WR1339, oleic acid, free fatty acid-free bovine serum albumin, and bovine milk lipoprotein lipase (LPL) were from Sigma. [ 14 C]Acetate, and ECL chemiluminescence detection kits for Western blots were purchased from Amersham Life Science (Little Chalfont, Buckinghamshire, United Kingdom).
Transgenic Mice-Hemizygous human apoE3 transgenic mice (ICR strain) were produced at the Gladstone Institute of Cardiovascular Disease with a DNA construct containing human apoE3 genomic DNA and the hepatic control region (15) . Homozygous apoE knockout (mE0) and homozygous LDL receptor knockout (LDLR0) mice (C57BL/6 strain) were purchased from The Jackson Laboratories (Bar Harbor, ME). ApoE and LDL receptor double-knockout mice (mE0/LDLR0) were generated in our laboratory by crossbreeding apoE knockout mice with LDL receptor knockout mice.
Male transgenic mice expressing low (apoE3 ϭ 8 mg/dl; E3low) or high (apoE3 ϭ 22 mg/dl; E3high) levels of human apoE3 were crossbred with female apoE knockout mice (mE0) to generate apoE3 transgenic mice without endogenous mouse apoE (E3low/mE0 and E3high/mE0). The human apoE3 transgene was detected by immunoblotting plasma (1 l) with human-specific anti-apoE polyclonal antiserum (16) . Mouse apoE deficiency was established by Western blotting with mouse-specific anti-apoE antiserum (provided by Dr. Jan Borén, Gladstone Institute of Cardiovascular Disease). In some cases, E3low/mE0 or E3high/ mE0 mice were crossbred with LDL receptor-null mice lacking mouse apoE (mE0/LDLR0) to generate E3low/mE0 or E3high/mE0 mice on a heterozygous (E3low/mE0/LDLR1 or E3high/mE0/LDLR1) or a homozygous (E3low/mE0/LDLR0 or E3high/mE0/LDLR0) LDL receptor-null background. LDL receptor deficiency was assessed by polymerase chain reaction with specific primers designed to identify both the altered and the unaltered gene sequences (17) .
Human Subjects-Human subjects were selected from the PROCAM Study group (6) at the Arteriosclerosis Research Institute, University of Mü nster, Mü nster, Germany. Type IV hyperlipidemic subjects (n ϭ 27) were defined as having plasma triglycerides Ͼ200 mg/dl and LDL cholesterol Ͻ140 mg/dl (18) . Normolipidemic subjects (n ϭ 6) were defined as having plasma triglycerides Ͻ200 mg/dl and LDL cholesterol Ͻ140 mg/dl.
Lipoprotein Separation and Analysis-Mouse blood was collected from the tails of 8 -16-week-old mice that had been fasted for 5 h. Human blood was collected from normolipidemic and type IV hyperlipidemic subjects after an overnight fast; EDTA was used as an anticoagulant. Plasma was obtained by centrifugation at 14,000 rpm (microcentrifuge) for 10 min (mouse samples) or at 3000 rpm for 15 min (human samples) at 4°C. Cholesterol and triglyceride levels were measured on total plasma and on chromatographic fractions by an enzymatic colorimetric method adapted for use with a microplate reader (19, 20) .
Lipoproteins of mouse or human plasma (100 l) were separated by chromatography on a Superose 6 column as described previously (16, 21 [28] [29] [30] [31] [32] [33] HDL) . To analyze the distribution of apoE in various lipoproteins, the pooled samples representing different lipoprotein classes were separated on a 12% polyacrylamide gel-SDS followed by immunoblotting with anti-human apoE antiserum. For analysis of chemical compositions and lipolysis of VLDL, the VLDL (d Ͻ 1.006 g/ml) were isolated from both mouse and human plasma by ultracentrifugation at 100,000 rpm for 2 h at 4°C in a Beckman TL100 ultracentrifuge (22) . Cholesterol and triglyceride levels were measured as described above. Apolipoproteins were separated on 10 -20% polyacrylamide-SDS gradient gels. The amounts of human or mouse apoE and human or mouse apoC-II were determined by Western blotting with polyclonal antibodies against human apoE, mouse apoE, human apoC-II, and mouse apoC-II, respectively (kindly provided by Dr. Karl Weisgraber, Gladstone Institute of Cardiovascular Disease) (17, 23, 24) . Purified human apoE, mouse apoE, human apoC-II, and mouse apoC-II were used as standards, respectively (provided by Dr. Karl Weisgraber).
VLDL Triglyceride Production in Vivo-Hepatic VLDL triglyceride production was determined with the Triton WR1339 method (25, 26) . Briefly, nontransgenic or various apoE3 transgenic mice were injected intravenously with 500 mg of Triton WR1339 (300 mg/ml in 0.9% NaCl) per kg of body weight after an overnight fast. Blood samples (50 l) were collected 0, 15, 30, 60, and 90 min later. Plasma triglyceride concentrations were measured as described above. The hepatic VLDL triglyceride production rate was calculated from the slope of the curve and presented as mol/h/kg.
VLDL Triglyceride Production in Vitro in ApoE-transfected Rat
Hepatoma Cells-To determine the effects of apoE expression levels on VLDL triglyceride production in vitro, rat hepatoma cells (McA-RH7777) were cotransfected with various apoE isoform genomic DNA and a neomycin gene (27) . Stably transfected colonies were selected by culturing the cells in medium containing G418 (400 g/ml) for 2 weeks. Positive colonies were characterized by a reverse transcriptasepolymerase chain reaction with primers specific for the human apoE gene and by anti-human apoE immunoblotting. Over 140 colonies were screened, and three transfected cell lines for each apoE isoform, which had matched apoE secretion levels, were selected for study.
VLDL triglyceride production rates were determined by incubating nontransfected and transfected cells with Dulbecco's modified Eagle's medium containing 1% bovine serum albumin, 1 mM oleic acid, and [ 14 C]acetate (5 Ci/ml) at 37°C for 4 h (26) in the absence or presence of 12 units/ml heparinase (28) . After incubation, the media were collected, and VLDL were isolated by ultracentrifugation at d Ͻ 1.006 g/ml. Lipids were extracted from VLDL with chloroform/methanol (2:1), separated by thin-layer chromatography, and quantitated by measuring the radioactivity of each fraction.
Lipolysis of VLDL in Vitro-To determine the ability of normal and apoE-enriched VLDL to serve as substrates for lipase-mediated lipolysis, various VLDL samples (30 g of triglycerides) were incubated with 1 g of bovine milk LPL or 50 l of hepatic lipase-transfected cellconditioned medium for 30 min at 37°C. In some cases, specific amounts of purified human apoE3 or apoC-II were included in the incubation (23) . After incubation, the levels of released free fatty acids were determined by an enzymatic colorimetric method (29) (Wako Chemicals, Richmond, VA).
RESULTS
In studying the effects of apoE on triglyceride-rich lipoprotein metabolism, we found that hepatic overexpression of human apoE3 at high levels (ϳ30 mg/dl) in transgenic mice lacking endogenous mouse apoE (E3high/mE0) led to mild HTG (an ϳ3-fold increase in plasma triglycerides versus nontransgenic mice) without significant changes in plasma total cholesterol ( Table I ). In contrast, low levels of apoE3 expression (ϳ13 mg/dl) on the same genetic background (E3low/mE0) did not alter plasma triglyceride levels significantly (Table I, Fig. 1B ). The E3high/mE0 mice had increased VLDL triglyceride and cholesterol and decreased HDL cholesterol (Fig. 1, C versus A) , with accumulation of apoE3 in the VLDL fraction (Table I) . Thus, overexpression of apoE3 in transgenic mice alters the plasma lipoprotein profile to one that resembles the human HTG phenotype. To determine if further accumulation of apoE3 in mouse plasma would exacerbate the HTG, we crossed the E3high/mE0 mice with LDL receptor knockout mice (LDLR0) to eliminate one of the pathways for apoE clearance. Removing one (E3high/ mE0/LDLR1) and then both (E3high/mE0/LDLR0) LDL receptor alleles increased plasma apoE3 by 50% and 80% (Table I) and plasma triglyceride levels by ϳ3-and ϳ4-fold, respectively, compared with the E3high/mE0 mice. VLDL cholesterol and triglycerides also increased significantly (compare Fig. 1 , C with E and F). Thus, additional accumulation of apoE3 caused by the LDL receptor deficiency further exacerbates the apoE3 overexpression-induced HTG phenotype. Interestingly, removal of LDL receptors from the E3low/mE0 mice did not significantly alter plasma triglyceride levels, possibly because the apoE3 levels were not elevated sufficiently to affect triglyceride levels (Table I) . Thus, rather than an absence of LDL receptors, an increased apoE3 level seems to be an important determinant of plasma triglyceride metabolism. In fact, plasma triglycerides correlated positively with apoE levels in apoE3 transgenic mice (Fig. 2A) . Triglyceride levels increased ϳ11-fold as plasma apoE3 rose from ϳ10 to ϳ55 mg/dl ( Fig. 2A) .
At least two mechanisms could explain the HTG associated with apoE3 overexpression: stimulated VLDL triglyceride production and impaired VLDL lipolysis. To ascertain if apoE3-overexpressing mice had increased VLDL triglyceride production, a characteristic of human HTG (2, 7), we determined in vivo VLDL triglyceride production rates in various apoE3 transgenic mouse lines using intravenous administration of Triton WR1339 to inhibit lipolysis (25) . The E3high/mE0 mice had a 50% increase in VLDL triglyceride production rate compared with nontransgenic mice, whereas the E3low/mE0 mice had no significant change (Table I ). The VLDL triglyceride production rate correlated positively with plasma apoE levels (Fig. 2B) , suggesting that apoE3 overexpression-induced HTG is at least partially due to stimulation of VLDL triglyceride production.
The effect of apoE on VLDL synthesis and/or secretion was further established by expressing different levels of apoE2, E3, or E4 in rat hepatoma cells (McA-RH7777). Three transfected cell lines were selected for each apoE isoform according to their expression levels of apoE, which varied over 7-fold from lowest to highest (Table II) . Interestingly, expression levels of endogenous rat apoE were not changed by overexpressing human apoE. Increasing levels of apoE expression actually resulted in decreased VLDL triglyceride secretion into the medium. However, an increase in apoE likely stimulates the reuptake of secreted VLDL via the heparan sulfate proteoglycan/LDL receptor-related protein pathway (12, 28) . Treatment of the transfected cells with heparinase to block this pathway (28) clearly resulted in a dose-dependent increase in VLDL triglyceride secretion (Table II) . Thus, an increase in apoE expression by the hepatoma cells correlates with increased VLDL synthesis and/or secretion. Similar results were obtained with all three apoE isoforms, confirming that the effect is independent of isoform type.
However, the VLDL triglyceride production rate in the E3high/mE0/LDLR0 mice did not differ significantly from that of the E3high/mE0 mice, even though the former had 4-fold higher plasma triglyceride levels than the latter (Table I) . Thus, VLDL triglyceride overproduction is only one aspect of the mechanism(s) responsible for the severe HTG in E3high/ mE0/LDLR0 mice. The increase in plasma triglycerides and VLDL cholesterol with the simultaneous decrease in LDL and HDL cholesterol in the presence of increasing levels of apoE3 in the E3high/mE0/LDLR1 and E3high/mE0/LDLR0 mice raised 
FIG. 2. Correlation of plasma or VLDL apoE with plasma triglyceride levels, VLDL triglyceride production, or VLDL lipolysis.
A, plasma apoE versus plasma triglyceride levels in apoE3 transgenic mice (r ϭ 0.92, p Ͻ 0.001, n ϭ 52). B, plasma apoE versus VLDL triglyceride production rates in apoE3 transgenic mice (r ϭ 0.91, p Ͻ 0.001, n ϭ 12). C, plasma apoE versus plasma triglyceride levels in human subjects (r ϭ 0.93, p Ͻ 0.001, n ϭ 38). D, VLDL apoE versus VLDL lipolysis in human subjects (r ϭ Ϫ0.77, p Ͻ 0.001, n ϭ 38).
the possibility that the accumulation of apoE3 impaired the lipolytic conversion of VLDL to LDL, as previously suggested for apoE2 (23, 30 -33) . To test this hypothesis, we examined the abilities of normal and transgenic VLDL containing various amounts of apoE3 (Table I) to serve as substrates for lipasemediated lipolysis in vitro (Fig. 3A) . Accumulation of apoE3 in transgenic VLDL from E3high/mE0, E3high/mE0/LDLR1, and E3high/mE0/LDLR0 mice inhibited LPL-mediated lipolysis by 48, 83, and 86%, respectively, compared with the VLDL from nontransgenic mice. Hepatic lipase-mediated lipolysis was affected to a lesser degree. Thus, apoE3-enriched VLDL, like apoE2-enriched VLDL (23) , are a poorer substrate for LPLmediated lipolysis than normal VLDL. The inhibitory effect of apoE3 on lipolysis was confirmed by adding increasing amounts of purified human apoE3 to nontransgenic VLDL (Fig.  3B) . More than 90% of LPL-mediated lipolysis was inhibited at the highest apoE3 levels.
To explain the inhibitory effect of apoE3 on lipolysis, we found that apoC-II content in the transgenic VLDL decreased gradually with increasing amounts of apoE3 (Table I) , suggesting that apoE3 accumulation in the VLDL may displace apoC-II (34), a well-defined cofactor for LPL activity (35) . To address this possibility, we added purified human apoC-II to various VLDL and determined its effects on lipolysis (Fig.  3C) . Adding apoC-II to apoE3-enriched VLDL stimulated LPL-mediated lipolysis in a dose-dependent manner, indicating that apoE3-impaired lipolysis of VLDL can be at least partially corrected by increasing the amount of apoC-II on the particles.
To test apoE involvement in the development of HTG in humans, we examined plasma samples from 27 patients with HTG and six normal controls (Table III) . Consistent with previous reports (3, 14) , the HTG subjects had increased plasma triglycerides, increased VLDL cholesterol and triglycerides, and decreased HDL cholesterol (Table III; compare Fig. 4, A  and B) . Plasma apoE levels were 2.5-4-fold higher in the HTG patients than in normal control subjects, suggesting that overexpression and/or accumulation of apoE occurs in the HTG patients. As in apoE3 transgenic mice, plasma triglyceride levels and plasma or VLDL apoE levels were positively correlated (Fig. 2C ), as were increased plasma triglyceride levels and VLDL apoE (r ϭ 0.94, p Ͻ 0.001). Furthermore, plasma or VLDL apoE correlated negatively with VLDL lipolysis (Fig. 2D) and HDL cholesterol levels (r ϭ Ϫ0.51, p Ͻ 0.001 and r ϭ Ϫ0.55, p Ͻ 0.001, respectively) (Table III) . These data suggest that accumulation of apoE in the VLDL of HTG patients also impairs LPL-mediated lipolysis.
To confirm that the increase in apoE impairs LPL-mediated lipolysis, we compared the lipolytic conversion of VLDL to LDL in HTG plasma with that in normal plasma. Autologous VLDL were added to normal plasma to increase VLDL triglyceride to the level in the HTG plasma (compare Fig. 4, B and D) . We then added 4 g of LPL to each of the samples and incubated them at 37°C for 1 h. As shown in Fig. 4 , C versus E, the VLDL in the HTG plasma were resistant to lipolytic processing compared with VLDL in normal plasma.
To determine whether the increased plasma apoE levels cause or result from increased triglycerides, purified human apoE3 was added to normal control plasma to levels similar to those in the HTG patients (14 mg/dl), and the effects of the increased apoE3 on VLDL lipolysis were determined. The increased apoE3 in the VLDL (2.5-fold) resulted in a 3-fold reduction in the apoC-II content of the VLDL and a marked impairment of LPL-mediated lipolysis of the VLDL (Table III) . Furthermore, apoE3 added to control plasma containing autologous VLDL resulted in an impaired lipolytic processing of VLDL to LDL (compare Fig. 4, E and F) . In contrast, adding apoC-II to the VLDL from HTG patients (Type IV-2ϩapoC-II, Table III ) returned lipolysis to nearly normal levels. Taken together, these results indicate that HTG patients have a disturbance in lipoprotein metabolism similar to that of trans- genic mice overexpressing apoE3 on either the mE0 or LDLR0 background (i.e. increased plasma and VLDL apoE, elevated plasma triglycerides and VLDL, decreased HDL, impaired VLDL lipolysis, and probably also increased VLDL triglyceride production) (2, 7).
DISCUSSION
Our combined mouse and human data imply that overexpression and accumulation of apoE cause HTG by stimulating VLDL triglyceride production and by impairing VLDL lipolysis. Several other lines of evidence support this conclusion. First, clinical studies have shown that plasma apoE concentrations account for 20 -40% of the variability of triglyceride levels in humans (13) , indicating an important role of apoE in modulating plasma triglyceride levels. Second, apoE-deficient mouse hepatocytes, in vitro and in vivo, have impaired secretion of VLDL triglycerides, suggesting a physiological role for apoE in the VLDL assembly-secretion process (26) . Thus, overexpression of apoE in the liver may stimulate VLDL production, leading to increased VLDL triglyceride secretion, as demonstrated in apoE3 transgenic mice and apoE-transfected hepatocytes in this study and in HTG patients. Third, apoE inhibits lipolysis in vitro (36, 37) , and plasma from HTG patients displays decreased LPL-cofactor activity for apoC-II (38) . As demonstrated in this study, the ratio of apoE to apoC-II in VLDL may be a critical determinant for LPL-mediated lipolysis of VLDL.
The low levels of HDL cholesterol in the apoE3-overexpressing mice are also common in HTG patients (1) (2) (3) . Impairment of VLDL lipolysis by apoE enrichment provides a partial logical explanation for this phenomenon. Since the formation of at least a portion of HDL particles requires the surface components of triglyceride-rich lipoproteins released during lipolytic processing (39) , apoE accumulation-associated impairment of lipolysis would lead to less release of surface components from the triglyceride-rich lipoproteins, which in turn would decrease the production of HDL particles.
Recently, a mouse model of familial combined hyperlipidemia (FCHL) was established by overexpressing the human apoC-III transgene on a LDL receptor knockout background (CIII/LDLR0) (40) . These mice displayed several characteristics of human FCHL, including increased plasma levels of total cholesterol, triglycerides, VLDL, and LDL. The CIII/LDLR0 mice and our E3high/mE0/LDLR0 mice have both similarities and differences. Plasma levels of triglycerides and VLDL were increased in both, but LDL were increased in the CIII/LDLR0 mice and decreased in the E3high/mE0/LDLR0 mice. The differences in LDL concentrations, also a major phenotypic difference between human FCHL and HTG, may reflect the different metabolic impacts of apoC-III and apoE. Apolipoprotein C-III raises plasma levels of triglycerides by delaying the clearance of VLDL (25, 41) and chylomicrons (34) , probably by displacing apoE from the particles (34). The increased VLDL will be TABLE III Lipid and apoE levels in plasma and VLDL from normal or type IV hyperlipidemic human subjects VLDL cholesterol and triglyceride and HDL cholesterol were calculated from the Superose 6 chromatography profiles of plasma lipoproteins by summing the individual fractions (Fig. 4, A and B) . FFA, free fatty acids; TC, total cholesterol; TG, triglycerides. c Purified human apoC-II (16 g) was added to VLDL (30 g of triglycerides) isolated from plasma of type IV-2 subjects and its effect on LPL-mediated lipolysis was determined.
FIG. 4. Superose 6 chromatography of 100 l of human plasma.
The cholesterol and triglyceride distributions in the plasma of individual subjects were analyzed as described previously (16) . Each panel is one representative profile of several analyzed in each group of human subjects. A, normal control plasma; B, plasma from a type IV hyperlipidemic subject; C, the same plasma in panel B after in vitro lipolysis by LPL. Plasma (300 l) was incubated with 4 g of bovine milk LPL for 1 h at 37°C. D, normal control plasma supplemented with autologous VLDL before in vitro lipolysis. E, the same sample as panel D after in vitro lipolysis. The sample was incubated with 4 g of bovine milk LPL for 1 h at 37°C. F, the sample from panel D was first incubated with purified apoE3 (at a final concentration of 14 mg/dl) for 20 min at 37°C and then incubated with 4 g of bovine milk LPL for another 1 h at 37°C. TC, total cholesterol; TG, triglyceride. The units for apoE, TC, and TG are mg/dl. converted by lipolysis to LDL, leading to increased LDL levels, especially when there is low LDL receptor activity (40) . In contrast, apoE is a ligand for the LDL receptor, cell-surface heparan sulfate proteoglycans, and the LDL receptor-related protein (12) . Thus, apoE accumulation in the VLDL would effectively mediate the clearance of the VLDL from plasma and, at the same time, impair lipolytic processing of the VLDL to LDL. The combined effect of apoE on VLDL clearance and lipolysis would result in decreased LDL. In fact, plasma LDL cholesterol levels in HTG patients are normal or slightly decreased (3, 14) . Finally, impairment of VLDL lipolysis by apoE accumulation may also contribute to the development of HTG in FCHL patients. Significantly increased levels of plasma and VLDL apoE were observed in FCHL patients (14) and FCHL mice (40) .
Together with previous observations from apoE-deficient humans and mice (42) (43) (44) (45) , our data indicate that optimal expression of apoE is crucial for maintaining normal metabolism of triglyceride-rich lipoproteins. Too little apoE impairs the clearance of triglyceride-rich lipoproteins and their remnants from plasma. Too much apoE stimulates VLDL triglyceride production in the liver and impairs LPL-mediated lipolysis, leading to HTG. Our HTG mice with apoE3 overexpression and accumulation appear to be valuable models of the HTG phenotype and should be useful for future studies of this disorder and possible therapies. Our studies suggest that the regulatory elements of the apoE gene may be potential therapeutic targets.
